SPORE in Lymphoma
淋巴瘤中的孢子
基本信息
- 批准号:8321631
- 负责人:
- 金额:$ 229.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:ArizonaB-Cell NonHodgkins LymphomaB-LymphocytesBiological ModelsBiologyCancer CenterCellsClinicalClinical TrialsCorrelative StudyDevelopmentDiffuseIn VitroLeadLymphomaMantle Cell LymphomaNon-Hodgkin&aposs LymphomaOxidation-ReductionPathologicProteasome InhibitorResearch PersonnelResearch Project GrantsResistanceResourcesSouthwest Oncology GroupTherapeuticTherapeutic AgentsTimeTranslational ResearchUniversitiesaurora kinasebasedesignnovelprograms
项目摘要
This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include:
Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma,
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL.
Project 3: Potentiating Proteasome Inhibitor Activity in NHL.
Project 4: Characterization of Lymphoma-lnitiating Cells.
罗切斯特大学詹姆斯·P·威尔莫特癌症中心(JPWCC)和亚利桑那大学亚利桑那癌症中心(ACC)的这一淋巴瘤孢子应用程序提供了一个基础广泛的转化性研究计划,研究淋巴瘤生物学中几个尚未解决的主要问题。具体地说,这些项目将侧重于几种正在开发或已批准用于治疗三种最常见的非霍奇金淋巴瘤的新型、有针对性的治疗药物,即弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤。我们首先将在体外和精心开发的模型系统中阐明作用和/或耐药性的机制;然后将设计和进行试验性临床试验,重点是相关研究,以验证这些机制。JPWCC和ACC的调查人员是两个项目的长期合作者,领导着每个项目。西南肿瘤组淋巴瘤委员会的临床和病理资源也被整合到这个项目中。项目包括:
研究项目1:侵袭性B细胞性非霍奇金淋巴瘤靶向Aurora Kinase,
项目2:优化氧化还原调节作为非霍奇金淋巴瘤的治疗策略。
项目3:增强非霍奇金淋巴瘤的蛋白酶体抑制活性。
项目4:淋巴瘤激发细胞的特征。
项目成果
期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
- DOI:10.1158/1078-0432.ccr-11-2413
- 发表时间:2012-04-15
- 期刊:
- 影响因子:0
- 作者:Mahadevan D;Stejskal A;Cooke LS;Manziello A;Morales C;Persky DO;Fisher RI;Miller TP;Qi W
- 通讯作者:Qi W
Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide.
- DOI:10.1371/journal.pone.0008115
- 发表时间:2009-12-02
- 期刊:
- 影响因子:3.7
- 作者:Skalska J;Brookes PS;Nadtochiy SM;Hilchey SP;Jordan CT;Guzman ML;Maggirwar SB;Briehl MM;Bernstein SH
- 通讯作者:Bernstein SH
Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.
- DOI:10.1309/ajcp2z0tagmuyjeb
- 发表时间:2013-02
- 期刊:
- 影响因子:3.5
- 作者:Valentino C;Kendrick S;Johnson N;Gascoyne R;Chan WC;Weisenburger D;Braziel R;Cook JR;Tubbs R;Campo E;Rosenwald A;Ott G;Delabie J;Jaffe E;Zhang W;Brunhoeber P;Nitta H;Grogan T;Rimsza L
- 通讯作者:Rimsza L
Update on aurora kinase inhibitors in gynecologic malignancies.
- DOI:10.2174/157489208786242322
- 发表时间:2008-11
- 期刊:
- 影响因子:2.8
- 作者:Tao X;Chon HS;Fu S;Kavanagh JJ;Hu W
- 通讯作者:Hu W
Demonstration of array-based analysis for highly multiplexed PCR assays application to detection of IGH@-BCL2 translocations in FFPE follicular lymphoma specimens.
演示基于阵列的高度多重 PCR 检测分析应用于检测 FFPE 滤泡性淋巴瘤标本中的 IGH@-BCL2 易位。
- DOI:10.1016/j.jmoldx.2010.11.019
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Spence,JaniceM;Rothberg,PaulG;Wang,Nancy;Burack,WRichard
- 通讯作者:Burack,WRichard
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN H BERNSTEIN其他文献
STEVEN H BERNSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN H BERNSTEIN', 18)}}的其他基金
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
8068292 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
P- 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
P- 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
7507431 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7373337 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
8260463 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7817051 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7628573 - 财政年份:2008
- 资助金额:
$ 229.93万 - 项目类别:
VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA
非霍奇金淋巴瘤患者的疫苗
- 批准号:
6166390 - 财政年份:2000
- 资助金额:
$ 229.93万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8131040 - 财政年份:
- 资助金额:
$ 229.93万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8381186 - 财政年份:
- 资助金额:
$ 229.93万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8321622 - 财政年份:
- 资助金额:
$ 229.93万 - 项目类别: